Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial

IMPORTANCE: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. OBJECTIVE: To examine whether T-VEC in combination with pembrolizumab is ass...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Oncol
Main Authors: Kelly, Ciara M., Antonescu, Cristina R., Bowler, Timothy, Munhoz, Rodrigo, Chi, Ping, Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Movva, Sujana, Dholakia, Reena, Ahmad, Hamza, Biniakewitz, Matthew, Condy, Mercedes, Phelan, Haley, Callahan, Margaret, Wong, Phillip, Singer, Sam, Ariyan, Charlotte, Bartlett, Edmund K., Crago, Aimee, Yoon, Sam, Hwang, Sinchun, Erinjeri, Joseph P., Qin, Li-Xuan, Tap, William D., D’Angelo, Sandra P.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2020
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990941/
https://ncbi.nlm.nih.gov/pubmed/31971541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6152
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים